Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today that Robert J. Perez and Timothy R. Franson, M.D., have joined the company’s Board of Directors. “Mr. Perez and Dr.

Proceeds Will Advance Novel Anti-Infectives into Clinical Studies Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the completion of a $42 million private Series B financing.

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, announced today the appointments of Paul Daruwala as chief commercial officer and James Balkovec, Ph.D. as senior vice president, Research.

Cidara has been named by FierceBiotech as one of 2014’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. “Welcome back Jeff Stein and Kevin Judice, two biotech execs who are part of the new biotech redux generation,”

Results from nonclinical studies of Cidara’s lead candidate CD101 IV (formerly biafungin), a novel, long-acting echinocandin, will be presented this week at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in Washington D.C.

Veteran team to apply novel, small molecule immunotherapy platform to treat severe fungal infections in immune compromised patients. Cidara has completed a $32 million Series A financing that will enable it to advance candidates from the company’s Cloudbreak™ targeted immunotherapy platform and